Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics

Polo-like kinase (PLK) family members play important roles in cell-cycle regulation. The founding member PLK1 is oncogenic and preclinically validated as a cancer therapeutic target. Paradoxically, frequent loss of chromosome 5q11–35, which includes PLK2, is observed in basal-like breast cancer. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yang, Kabotyanski, Elena B., Shepherd, Jonathan H., Villegas, Elizabeth, Acosta, Deanna, Hamor, Clark, Sun, Tingting, Montmeyor-Garcia, Celina, He, Xiaping, Dobrolecki, Lacey E., Westbrook, Thomas F., Lewis, Michael T., Hilsenbeck, Susan G., Zhang, Xiang H.-F., Perou, Charles M., Rosen, Jeffrey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827906/
https://www.ncbi.nlm.nih.gov/pubmed/35156101
http://dx.doi.org/10.1158/2767-9764.CRC-21-0106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827906/
https://www.ncbi.nlm.nih.gov/pubmed/35156101
http://dx.doi.org/10.1158/2767-9764.CRC-21-0106

Ejemplares similares